KL130008

KL130008 is a novel, orally administered small molecule inhibitor that selectively targets Janus kinase 1 and Janus kinase 2 (JAK1/2). It is being developed primarily for the treatment of autoimmune diseases, including rheumatoid arthritis and alopecia areata. The drug acts by inhibiting JAK1/2-mediated signaling pathways, which play a key role in the pathogenesis of these conditions. In clinical studies, KL130008 demonstrated dose-dependent inhibition of phosphorylated STAT3 (p-STAT3), indicating effective suppression of JAK signaling. The compound has shown favorable pharmacokinetics with rapid absorption and a half-life of approximately 14–18 hours. Safety data from phase I trials indicate that it is generally well tolerated, with most adverse events being mild or moderate in severity and resolving without intervention[1][2][8].